
PSE and RCPE Announce Pharma Centre of Excellence
Process Systems Enterprise (PSE), the Advanced Process Modelling company, and the Research Center for Pharmaceutical Engineering GmbH (RCPE), an independent R&D Centre specialised in Advanced Manufacturing Science and Pharmaceutical Engineering, today announced the formation of a Centre of Excellence (CoE) aimed at bringing combined model-based analytical technology and services to pharmaceuticals manufacturers.
The CoE for Pharmaceutical Formulation & Manufacture provides a single-point service for material characterisation, predictive modelling and process optimisation. It aims to help pharmaceutical companies accelerate the development of drugs and their manufacturing processes, from R&D through tech transfer to commercial manufacturing. Further detail on the CoE and the services it provides to pharmaceutical drug development is also outlined in this webinar.
The combined, integrated service will provide solutions that help pharma organisations to explore the formulation and manufacturing decision space rapidly and effectively using mechanistic modelling approaches. By combining models and experimental data to provide an accurate predictive capability for drug products and their manufacture the CoE will be able to help companies accelerate formulation decisions and design more effective and efficient manufacturing processes.
PSE provides the gPROMS FormulatedProducts modelling suite, which contains mechanistic models for drug substance manufacture, drug product manufacture and in-vitro/vivo product performance as well as specific capabilities for optimising product and process design. The company pioneered the emerging science of Systems-based Pharmaceutics, and is the leader of the £20.4m digital design ADDoPT project.
RCPE performs cutting-edge research in process and product optimisation to help create competitive advantage through development of novel products and production processes, with a key focus being new drug delivery systems. The company has extensive experimental and processing facilities in Graz, Austria that include analytical science, material science, PAT and pharmaceutical engineering capabilities, and has significant experience in modelling and simulation of fluid and granular/powder systems.
Massimo Bresciani, Executive Director for Scientific Operations & BD of RCPE, says “we are very excited about the Centre of Excellence. It gives us a truly unique capability and allows us to provide the most modern set of integrated tools and services for product and process design and development. By using both parties’ experience we can, for example, help pharma companies speed up tech transfer and late phase filings”.
Sean Bermingham, VP for PSE’s Formulated Products Business says “the combination of mechanistic models and targeted experiments is a powerful approach that helps pharma companies accelerate drug substance and product development, quantify and manage risk, and design and scale-up robust manufacturing processes. We very much look forward to working with RCPE to provide a holistic service that covers all these aspects”.
Watch this webinar for more information on the CoE.
‘About’: www.psenterprise.com/news/pr161202; www.rcpe.at
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005852/en/
Contact information
PSE
Kate Burness, +44-20-8563-0888
k.burness@psenterprise.com
or
RCPE
Gertraud
Krug, +43.316-873-30987
gertraud.krug@rcpe.at
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo